Petros Pharmaceuticals, Inc. (PTPI) Stock Price & Analysis
Petros Pharmaceuticals, Inc. (PTPI) rose 18.18% to USD 0.01 as of June 10, 2026 at 02:30 UTC, according to Nexqual real-time market data.
PTPI last closed at USD 0.01; the session ranged USD 0.01–0.01 on volume of 229,159 shares. Market capitalization is $275,419, with a 52-week range of USD 0–0.04 (PNK). Source: Nexqual, June 10, 2026 at 02:30 UTC.
Key Statistics (as of June 10, 2026 at 02:30 UTC)
| Price | USD 0.01 |
|---|---|
| Change | ▲ 18.18% (up) |
| Previous Close | USD 0.01 |
| Open | USD 0.01 |
| Day Range | USD 0.01 – 0.01 |
| 52-Week Range | USD 0 – 0.04 |
| Volume | 229,159 shares |
| Market Cap | $275,419 |
| Exchange | PNK |
Technical Analysis (PTPI)
Nexqual's technical model rates PTPI "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 02:30 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 47.03 (neutral) |
| vs SMA50 | Below (USD 0.01) |
| MACD | -0 (negative) |
Analyst Ratings (PTPI)
Wall Street analysts rate PTPI "None", per Nexqual as of June 10, 2026 at 02:30 UTC.
| Consensus Rating | None |
|---|
Earnings (PTPI)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-09-30 | USD -13.25 vs est -7.25 ▼ miss |
| 2024-06-30 | USD -9.25 vs est -19.25 ▲ beat |
| 2024-03-31 | USD -42.25 vs est -36 ▼ miss |
| 2023-12-31 | USD -54.25 vs est -27.75 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:30 UTC.
Financials & Fundamentals (PTPI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 1.68 |
| Total Cash | $4.35M |
| Total Debt | $0 |
| Free Cash Flow | $-21.34M |
Source: Nexqual, June 10, 2026 at 02:30 UTC.
Financial Health Score (PTPI)
Nexqual rates Petros Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:30 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $4M cash, no debt |
| Cash Flow | Weak — FCF negative: -$21M, burning cash |
| Efficiency | Mixed — No data |
Ownership (PTPI)
| Insider Ownership | +17.89% |
|---|---|
| Institutional Ownership | +10.24% |
| Shares Outstanding | 42.37M |
| Float | 36.25M |
| Short % of Float | +25.07% |
Source: Nexqual, June 10, 2026 at 02:30 UTC.
Leadership (PTPI)
Petros Pharmaceuticals, Inc. is led by Joshua N. Silverman (age 55), Executive Chairman of the Board, per Nexqual as of June 10, 2026 at 02:30 UTC.
| Executive Chairman of the Board | Joshua N. Silverman (age 55) |
|---|---|
| President & Chief Commercial Officer | Fady Boctor (age 47) |
From Petros Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary software as a service (SaaS) platform and Software as a medical device web application designed to assist pharmaceutical companies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BFRI | Biofrontera Inc. | USD 0.88 | ▼ 5.88% |
| ISPC | iSpecimen Inc. | USD 2.92 | ▼ 3.31% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.58 | ▼ 0.85% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| LGVN | Longeveron Inc. | USD 0.77 | ▲ 5.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:30 UTC. This page is informational and not investment advice.